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Summary: The quantification of α-foetoprotein in dry blood spots from pregnant women was evaluated, using
a conventional radioimmunoassay (RIA) with a monospecific antibody. The stability of α-foetoprotein in dry
blood spots on filter paper was evaluated with respect to mailing, distances travelled, and the existence of
high summer temperatures in our region. The results obtained show that the blood α-foetoprotein is stable
on dry filter spots sent by mail and is stable for up to four weeks at 4, 25 and 37 °C. The analytical method
used has a minimal detectable concentration of 10 + 1.9 international kilo-units/I. Both inter- and intra-assay
variabilities are smaller than 10% and this method can provide results comparable with those of conventional
serum assays. Results from dry blood spots and serum samples (the latter analysed by both RIA and two-
site enzyme immunoassay) exhibited a good correlation (r = 0.98 and r = 0.97, p < 0.001). The design of
the assay and the nature of the samples make this method suitable for a screening programmes for the
antenatal detection of open neural tube defects.
Introduction
α-Foetoprotein is, besides albumin, the major protein
in foetal circulation. It consists of a single polypeptide
chain with 590 amino acids, 3.4--4% carbohydrate,
and a molecular weight of about 69000 (1). c^Foe-
toprotein testing for the detection of neural tube de-
fects is based on the observation, reported more than
a decade ago, that this protein is detectable in mater-
nal serum and amniotic fluid, and that, in the presence
of an open neural tube defect, its concentration mark-
edly exceeds normal limits (2—4). Neural tube defects
are among the most common birth defects, occurring
with a frequency of one to two cases per 1000 live
births, 95% of them with no prior family history of
such disorders (5 — 8).
Testing of α-foetoprotein in maternal serum provides
a means of screening the population for antenatal
diagnosis of neural tube defects. The test allows the
selection of women with high risk pregnancies. Thus,
if the maternal serum α-foetoprotein value is above
the norm for the population group to which the
patient belongs, a protocol of diagnosis is initiated,
including a second serum α-foetoprotein test, ultra-
sonography and amniotic fluid α-foetoprotein and
acetylcholinesterase tests (5 — 12). The most common
procedures used for maternal serum α-foetoprotein
testing have been radioimmunoassays (RIA) on serum
samples (13 —16). The measurement of α-foetoprotein
in dry blood spots, from newborn children and preg-
nant women, has been previously described for the
adaptation of RIA and immunoradiometric kits,
showing a good concordance between the dry blood
and serum RIA tests (17-19).
In this paper, we report our experience with the de-
velopment of a competitive single-antibody RIA as a
inexpensive method for α-foetoprotein determination
on dry blood spots. These samples were used in a
screening programme in our region with locations up
to 250 km apart. Its use eases the sending of samples
by mail. However, in summer the temperatures are
around 40 °C This necessitates a study of α-foeto-
protein stability in dry blood spots subjected to high
temperatures. We report the results obtained, recovery
and precision and the estimation of α-foetoprotein on
a wide population of pregnant women, using dry
blood spot samples.
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Materials and Methods
Specimens
1016 dry blood specimens from pregnant women were used in
this study. Blood samples, obtained by vein puncture, were
applied as 1 cm diameter spots to filter paper (No. 903
Schleicher and Schuell), air dried at room temperature and
routinely stored in plastic bags at 4 °C. For the assay, a disc,
6.5 mm in diameter, punched from between the center and edge
of each spot was placed directly into a 12 χ 75 mm polystyrene
test tube. Serum specimens were obtained from 200 pregnant
women and stored at —20 °C until their analysis. a-Foetopro-
tein concentrations were measured and the results were com-
pared with those for dry blood spot samples obtained from the
same individuals.
Preparation of samples
All dry blood spot specimens were eluted with a 50 mmol/1
phosphate-buffered saline solution (pH 7.5). The punched disc
was eluted by allowing it to stand for 16 hours at 4°C with
200 μΐ of the described phosphate buffered saline. Experiments
with 125I-labelled human α-foetoprotein showed that the ana-
lytical recovery of α-foetoprotein from dry blood spots was
better than 90%.
Stability of α-foetoprotein in dry blood spot samples
To determine the α-foetoprotein stability in the dry state we
spotted 10 blood samples from pregnant women on filter paper
as described above. After the initial concentrations had been
determined, the blood spots were stored at 4, 25 and 37 °C or
were air-mailed in summer to three cities up to 250 km away.
The mailed samples were returned by mail within one week
and α-foetoprotein levels in these samples and in those which
had been kept at 4, 25 and 37 °C, were determined.
Dry blood spot α-foetoprotein RIA components
Monospecific rabbit anti-human α-foetoprotein, as well as pur-
ified human α-foetoprotein were purchased from Dako Co.
(Santa Barbara, CA, USA). The α-foetoprotein was iodiiiated
with 125I using the method of Kirkpatrick & Nakamura (13).
The anti-human α-foetoprotein serum was titrated by incubat-
ing it in serial dilutions (1/1000 to 1/200000) with 175 pg of
125I-labelled α-foetoprotein in 0.1 mol/1 phosphate buffer, 1 g/1
ovalbumin, pH 7.5. The immunoprecipitating reagent (protein-
A-bearing Cowan I strain Straphylococcus aureus, 10 g/1) was
supplied by CSIC (Madrid, Spain). Dry blood standards were
prepared by diluting the WHO reference standard (12-388,
Statens Serum Institute, Copenhagen, Denmark) with a-foe-
toprotein-free whole blood, to give a final range from 0 to 320
international kilo-units/I of serum. Dry blood specimens were
then prepared as previously described and stored in plastic bags
at 4°C until further use. In the assay, the buffer used for
dilution of the antibody and the 125I-labelled α-foetoprotein was
50 mmol/1 phosphate buffered saline, 2.5 g/l valbumin, pH
Serum α-foetoprotein RIA components
These components are basically the same as those of the a-
foetoprotein RIA dry blood spots. In this case, however, the
reference standards were prepared in plasma instead of dry
blood and were kept at -20°C until their use (before 3
months). The buffer used for dilution of the serum sample, the
antibody and the I25I-labelled α-foetoprotein was 0.1 mol/1
phosphate buffer, 1 g/1 ovalbumin, pH 7.5.
Serum α-foetoprotein enzyme immunoassay compo-
nents
Monospecific rabbit anti-human α-foetoprotein (Dako, Co.,
Santa Barbara, CA, USA) was labelled with horseradish per-
oxidase, using the periodate oxidation conjugation method (20).
The same unlabelled antibody was immobilized on Dinatec
microelisa M-129 microplates (Florida, USA,). For this purpose,
100 μΐ of 1/100 antibody dilution (in phosphate buffered saline,
50 mmol/1, pH 7.2) was added to each well, followed by a 24
hour incubation period at 4 °C. The wells were then washed 3
times with 1 ml Tween 20 in 11 of 50 mmol/1 phosphate buffered
saline solution, and 200 μΐ of 5 g/1 human albumin in phosphate-
buffered saline, 50 mmol/1, pH 7.2, were added. After 4 hours
incubation at 25 °C, the content of the wells was discarded and
the microplates were stored at -^40 °C until use. The enzyme
label was assayed by oxidation of an o^phenylenediamine so-
lution composed of 0.1 mol/1 citrate buffer, pH 5.1, containing
5 mmol/l H2O2 and 16 mmol/1 o^phenylenediamine dihydro-
chloride (Sigma). The purified α-foetoprotein and serum a-
foetoprotein standards were the same as those used in the RIA
method.
Performance of the assays
Dry blood spots and serum samples were used for the a-
foetoprotein assay. Each spot was eluted into 200 μΐ of 2.5 g/1
ovalbumin and 0.5 mmol/1 thimerosal (Sigma Chemical Co.,
St. Louis, MO, USA) in 50 mmol/1 phosphate-buffered saline,
pH 7.5 (Buffer A), 100 μΐ of buffer A with 25 mmol/1 EDTA
(Merck, Darmstadt, GFR)) (Buffer B), and 100 μΐ of antiserum
in a final dilution of 1/25000. For serum α-foetoprotein RIA,
100 μΐ of 1/20 serum dilution were added to 100 μΐ of antibody
dilution and 100 μΐ of 0.1 mol/i phosphate buffer, 1 g/1 ovak
bumin, pH 7.5. After overnight incubation at 4°C, 100 μΐ of
125I-labelled α-foetoprotein (approx. 25000 counts/min) were
added and incubation continued for a further 72 and 48 hours
for dry blood spot and serum samples respectively. To precip-
itate the immune complexes, 1 ml of a solution containing 65
ml immunoprecipitating reagent in 1 1 of 50 mmol/1 phosphate^
buffered saline pH 7.5 was added to each tube, then centrifuged
(4000 g, 20 min, 4 °C), supernatants discarded, and the radio-
activity in the pellet measured in a gamma counter (Kontron
Analytical, M nchenstein, Switzerland). Data evaluation was
computer-aided, using a semi-logarithmic fit.
For the enzyme Immunoassay (ElA) determination, 100 μΐ of
50 mmol/1 phosphate-buffered saline, 5 g/1 bovine albumin, pH
7.2 and 10 μΐ of standard or serum samples were transfered to
a well coated with an anti-a-foetoprotein antibody. The mixture
was stirred and incubated for 1 hour at 37 °C, then the wells
were washed 3 times with the Tween 20 in phosphate^buffered
saline. Then, 100 μΐ of a 1/200 dilution of labelled antibody (in
50 mmol/1 phosphate-buffered saline, 5 g/1 bovine albumin, pH
7.2) were added to each well and the wells were incubated for
1 hour at 37 °C. The wells were washed 3 times again and
finally 100 μΐ of 0-phenylenediamine solution were added. After
30 min of incubation at 25 °C, the peroxid se activity was
stopped with 100 μΐ of 1 mol/1 H2SO4 and determined by meas^
uring the resulting colour at 492 nrn in a Titerket multiscand
spectrometer (Flow Laboratories, Ayrshire, Scotland).
Statistical methods
Results are expressed as mean ± standard error (SEM); stand-
ard deviation (SD) and coefficient of variation (CV) are also
included. Statistical analyses were performed using one-way
analyses Of variance (ANOVA); significant differences between
groups were determined by the Student Nq>yman Reuls test.
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Results
Assay sensitivity and precision
The standard RIA assay curve for dry blood spot
samples extended from 0 to 320 international kilo-
units/I (fig. 1). Using the formula given by Rodbard
(21) or 2 χ SD of blank measurement value, we de-
termined the lower limit of sensitivity to be 10 ± 1.9
international kilo-units/I (means ± SEM, n = 10) or
10.5 ±1.7 international kilo-units/I (means ± SEM,
n = 10), respectively. Within-run CVs of 19.5, 7.0 and
8.2% were determined by testing 10 discs from each
of three spots containing 10, 40 and 160 international
kilo-units/I, respectively. The respective between-run
CVs were 16, 7 and 10%.
standard stock material to α-foetoprotein-free whole
blood in amounts to cover the expected concentration
range. The amounts found were compared with those
calculated and the results are summarized in table 1.
Correlation
For our comparison study we used 200 dry blood and
serum samples from the same individuals, who were
pregnant women of 10 to 39 weeks gestation, a-
Foetoprotein contents in serum, determined by both
RIA and EIA methods, correlated significantly with
those obtained in the dry blood spots, as shown in
figures 2 and 3. The correlation coefficients obtained
were 0.98 and 0.97 (p < 0.001), respectively.
Recovery
Analytical recovery of WHO stock material was used
to assess the calibration accuracy of our method. For
this purpose, we added aliquots of WHO reference
Tab. 1. Recoveries of α-foetoprotein from dry blood spot sam-
ples.
a-Foetoprotein
(International kilo-units/I)
Expected
.10
40
160
Found
mean ± SD, n = 3
10.7 4- 2.6
43.8 + 2.5
163.6 + 8.7
Recovery (%)
mean ± SD, n
107.4 + 26.4
109.4+ 6.3
102.3 + 6.7
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Fig. 1. RIA calibration curve for α-foetoprotein. Results shown
are the mean ± SD of triplicates.
Fig. 2. Relationship between RIA serum and dry blood spot
results.
n = 157, y = - 1.76 + 1.03x, r = 0.98, p < 0.001.
Ο 50 100 150 200 250
Blood-spot α-foetoprotein (103IU/l]
Fig. 3. Relationship between EIA serum and dry blood spot
results,
η = 140, y « 1.56 - 0.92x, r = 0.97, p < 0.001.
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Stabi l i ty of α-foetoprotein in blood spot sam-
ples
The effect of mailing was analysed on 10 samples
which were obtained from pregnant women with ges-
tational age 5? 16 weeks (tab. 2). The test for signif-
icant differences of two samples was applied to three
groups, each including α-foetoprotein concentrations
initially obtained and those measured in dry blood
spots returned by mail from the three cities previously
described. No significant differences were found. Ta-
ble 2 shows both the initial concentrations and those
determined in mailed samples. Thermal stability at 4,
25 and 37 °C was analysed on the above described
samples. The results obtained were approximately the
$ame (fig. 4) and we did not observe significant
changes in the α-foetoprotein content between the
initial concentrations and those of the different groups
studied. The results obtained show that a-foetoprotein
in dry blood spots remains stable during mailing and
exposure to 4, 25, and 37 °C for at least four weeks.
Effect of haematocrit
We assessed the effect of haematocrit by assaying dry
blood specimens prepared from an initial blood sam-
ple, supplemented with α-foetoprotein to give ap-
proximately 20, 40, 80 and 160 international kilo-
units/I α-foetoprotein (tab. 4). The initial haematocrit
was 0.35 and we increased the haematocrit to 0.40
and 0.47 by removing part of the plasma. Haemato-
crits between 0.35 and 0.47 did not Affect the results
for α-foetoprotein in dry blood spot samples
(P < 0.05, Anova, file = 3, sample size = 60).
Tab. 2. Stability of α-foetoprotein in dry blood spots returned
by mail from three cities (a, b, c) from 120 to 250 km
from the laboratory.
Gestatioi
age
(weeks)
16
25
16
17
27
23
19
33
22
30
lal a-Foetoprotein
(International kilo^units/1)
Initial
16
65
40
5
58
13
21
73
41
47
Upon return by mail
a
19
64
43
4
60
14
20
77
40
49
b
19
64
40
4
55
15
24
75
42
49
c
15
67
42
3
61
11
22
79
39
46
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Fig. 4. Storage stability of α-foetoprotein at different temper-
atures.
Results shown are the mean ± SD, n = 10.
a) 4°C
b) 25 °C
c) 37 °C
Tab. 3. Effects of haematocrit on α-foetoprotein concentration.
α-Foetpprotein (International kilo-units/I)
mean ± SD, n == 5
Haematocrit 0.35
24.3 + 2.7
35.9 + 1.6
81.5 + 1.8
149.2 + 4.3
Haematocrit 0.40
21.1 ± 2.7
39.0 + 1.9
78.0 ± 2.4
146.0 + 5.5
Haematocrit 0.47
20.5 + 0.6
38.6 + 1.2
81.1 + 1.5
152.6 -l· 3.8
Tab. 4. Values obtained for α-foetoprotein in maternal dry
blood spot samples for patients screened at 16 to 20
weeks of pregnancy. Pregnancies subsequently involv-
ing neural tube defects, and multiple pregnancies Have
not been included in this table.
Gestational
weeks
15
16
17
18
19
20
age
number
37
43
43
34
43
34
Median Mean ± SD
International kilo-units/I
18
26
23
31
38
34
22.4 + 14.8
27.3 +Ί4.3
26.3 ± 13.9
35.1 -l· 18.6
43.9 -h 23.5
37.8 ± 18.8
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Clinical studies
We evaluated 1016 maternal blood spots from preg-
nant women for α-foetoprotein content. The pregnant
women were from an unselected population, ranging
from 5 to 42 weeks of gestation. The α-foetoprotein
maternal dry blood spot distribution throughout preg-
nancy is shown in figure 5. Concentrations of a-
foetoprotein are expressed as median and 2.5 χ me-
dian with respect to each gestational age. Table 4
shows values for median and mean ± SD, for ges-
tational weeks 15 to 20, obtained with the dry blood
spot samples. These specimens were from non-neural
tube defect singleton pregnancies seen at our hospital.
The gestational age of each pregnancy was defined as
the weeks of pregnancy completed from the first day
of the last menstrual period. The best time for de-
tecting open neural tube defects by measuring mater-
nal serum α-foetoprotein is at 16 to 18 weeks of
pregnancy (9). In 5 of 120 pregnant women (4.1%)
at 16 to 18 weeks of pregnancy, the serum α-foeto-
protein was high at 2.5 times the normal median.
1000
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ο
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35
Fig. 5. Dry blood spot rfoetopr tein levels as a function of
gestation weeks. Solid lines indicate the median and
; 2.5 χ median of the values obtained.
numerous analyses, e. g. for detecting inborn errors
of metabolism, congenital hypothyroidism, monitor-
ing concentrations of glucose, cholesterol and thera-
peutic drugs (22, 23). The essential drawback for a-
foetoprotein measurement on dry blood spots has
been the need of a reliable assay to ensure an effective
and accurate neural tube defect screening. Thus, al-
though the intitial reports showed a good correlation
between serum and dry blood tests, they also showed
poorer precision and recovery results in the second
kind of sample (17, 18, 19). However, mailing blood
samples dried on filter paper is more convenient and
easier than sending tubes of serum and is the most
effective laboratory method for a regional screening
programme. Therefore, our objective was to develop
a method for measuring maternal serum on dry blood
spots, improving the recovery and precision results
previously reported.
Mizejewski et al. (17) and Wong et al. (18) have
described the α-foetoprotein stability in dry blood
spot samples during mailing and exposure to 4 °C. In
our study we have shown that the α-foetoprotein is
stable even at higher temperatures (25 and 37 °C) and
we have confirmed α-foetoprotein stability in dry
blood spots by mailing in a region with mean tem-
peratures higher than those of the reported countries
(17,18). Moreover, we have found that increasing the
haematocrit does not affect the results for α-foeto-
protein, as also observed in a reported assay of theo-
phylline (22). In the assay, the sensitivity was not
better than reported previously for dry blood spots
(19), but we achieved better recovery than previously
reported (18), and we obtained coefficients of varia-
tion for 40 and 160 international kilo-units/I of less
than 10%. Besides, the α-foetoprotein results for dry
blood spots correlated well with those obtained for
serum samples, with no markedly discrepant results
even at high α-foetoprotein concentrations.
We think that this method could support the basis of
a screening programme for identifying pregnant
women with a high risk of neural tube defect. Rein-
forcing this hypothesis, we found 4.1% of pregnant
women with an intial maternal serum α-foetoprotein
of 2.5 χ median. This does not disagree with previ-
ously reported results (24—27).
Discussion
Currently, RIA or alternative techniques on serum
samples are used in screening for neural tube defects
by quantifying maternal serum α-foetoprotein. More-
over, dry blood spots have been used successfully in
Acknowledgement
This study was supported by a grant from the Servicio Andaluz
de Salud. We thank Miss Af. Prieto for help in preparing the
manuscript.
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 2
84 Gonzalez et al.: α-Foetoprotein assay using dry blood spot samples
 β
References
1. Morinaga, T., Sakai, M., Wegmann, T. G. & Tamaoki, T.
(1983) Proc. Nat. Acad. Sei. USA 80, 4604-4608.
2. Brock, D. J. M. & Sutcliffe, R. G. (1972) Lancet //, 197-
199.
3. Brock, D. J. M., Bolton, A. E. & Monaghan, J. M. (1973)
Lancet//, 923-924.
4. Leek, A. E., Ruoss, C. F., Kitau, M. J. & Chard, T. (1973)
Lancet //, 385.
5. Main, D. M. & Mennuti, M. T. (1986) Obstet. Gynecol.
67, 1-16.
6. Fuhrmann, W. & Weitzel, H. K. (1985) Hum. Genet. 69,
47-61.
7. Schnittger, A. & Kjessler, B. (1984) Acta Obstet. Gynecol.
Scand. 119, 5-47.
8. Collaborative study in Cuba and in the German Demo*
cratic Republic (1986) Human. Genet. 73, 60-63.
9. Report of U. K. Collaborative Study on Alpha-fetoprotein
in relation to Neural Tube Defects (1977) Lancet /, 1323-
1332.
10. Ferguson-Smith, M. A. (1983) Br. Med. Bull. 39, 365-
373.
11. Second Report of the U. K. Collaborative Study on Alpha-
fetoprotein in relation to Neural Tube Defects (1979) Lan-
cet//, 651-662.
12. Report of the Collaborative Acetylcholinesterase Study
(1981) Lancet/, 321-324.
13. Kirkpatrick, A. M. & Nakamura, R. M. (1981) In: Alpha-
fetoprotein. Laboratory procedures and clinical applica-
tions (Kirkpatrick, A. M. & Nakamura, R. M., eds.) Mas-
son Publishing. USA Inc., pp. 31 -59.
14. Ruoslahti, E., Uotila, A. & Engvall, E. (1982) Methods
Enzymol. 84, 3-5.
15. Brock, D. J. M., Bolton, A. E. & Scrimgeour, J. B. (1974)
Lancet /, 767-769.
16. Christensen, R. L., Rea, M. R., Kessler, G., Grane, J. P. &
Valdes, R. (1986) Clin. Chem. 32, 1812-1817.
17. Mizejewski, G. J., Bellisario, R., Betil wski, D. W. &
Carter, T. P. (1982) Clin. Chem. 28, 1207-1210.
18. Wong, P. Y., Mee, A. V. & Doran, T. A. (1982) Clin.
Biochem. 15, 170-172.
19. Dallaire, I., Grenier, A., Ducharme, G., Melacon, S. B.,
Potier, M. & Des Rochers, M. (1982) Prenat. Diagn. 2,
265-271.
20. Johnson, G. D., Holborow, E. J. & Darling, J. (1978) In:
Handbook of experimental immunology vol. 1, Imrmino-
chemistry (Weir, D. M., ed.) Scientific Publications Oxford,
pp. 15.1-15.30.
21. Rodbard, P. (1978) Aimal. Biochem. 90, 142.
22. Li, P. K., Lee, J. T., Coubpy, K. A. & Ellis, E. F. (1986)
Clin. Chem. 32, 552-555.
23. Little, R. R., Mckenzie, E. M., Wiedmeyer, H. M., England,
J. D. & Goldstein, D. E. (1986) CUn. Chern. 32, 869-871.
24. Gadner, S., Burton, B. K. & Johnson, A. M. (1981) Am.
J. Obstet. Gynecol. 140, 250-253.
25. Burton, B. K., Sowers, S. G. & Nelson, L. H. (1983) Am.
J. Obstet. Gynecol. 146, 439-444.
26. Polanska, N., Meads, B. W., Williams, D. L. & Orr, H.
(1981) Brit. Med. J. 283, 1604^-1605.
27. Nightingale, S. L. (1985) In: Genetic and the Law III
(Milunsky, A. & Annas, G. J., eds.) Plenum Press, New
York and London, pp. 395—403.
R. Goberna
Departmento de Bioquimica Clinica
Facuitad de Medicina
Universidad de Sevilla
Avda. Sanchez Pizjuan, 4
E-41009 Sevilla
J. Clin. Chem. Clin. Biochem. / Vol. 26,1988 / No. 2
